Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045588 | 0.92 | DPP4 (0.44) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL4043363 | 0.90 | DPP4 (0.46) | DPP4HDAC8FAPDPP8DPP9 | |
| SCHEMBL4045220 | 0.90 | DPP4 (0.42) | DPP4OPRD1SMYD3FAPDPP8 | |
| SCHEMBL5941806 | 0.86 | DPP4 (0.54) | DPP4HDAC8OPRD1OPRM1FAP | |
| SCHEMBL4041496 | 0.85 | CTSK (0.40) | DPP4OPRD1OPRM1DPP9 | |
| SCHEMBL4040770 | 0.85 | CTSK (0.48) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL4043002 | 0.84 | CTSK (0.45) | DPP4DPP9 | |
| SCHEMBL4044474 | 0.84 | CTSK (0.42) | DPP4 | |
| SCHEMBL4042769 | 0.84 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL4045825 | 0.83 | DPP4 (0.49) | DPP4HDAC8OPRD1OPRM1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | DPP4 3448/4885HDAC8 43/4885OPRD1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.